Luye Pharma Group Ltd (FRA:LUP) Stock Price, Trades & News

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.8
Equity-to-Asset	0.49
Debt-to-Equity	0.59
Debt-to-EBITDA	3.83
Interest Coverage	1.83
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	0.85	Distress Grey Safe
Beneish M-Score	-2.42	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-2.3
	3-Year EBITDA Growth Rate	6.4
	3-Year EPS without NRI Growth Rate	-20.4
	3-Year FCF Growth Rate	12.1
	3-Year Book Growth Rate	10.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	29.58
	Future 3-5Y Total Revenue Growth Rate Estimate	8.16

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	49.68
	9-Day RSI	46.1
	14-Day RSI	43.41
	3-1 Month Momentum %	-23.38
	6-1 Month Momentum %	-20.81
	12-1 Month Momentum %	-37.89

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.53
	Quick Ratio	1.44
	Cash Ratio	0.75
	Days Inventory	153.88
	Days Sales Outstanding	155.25
	Days Payable	141.09

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-5.1
	Shareholder Yield %	-13.46

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	65.98
	Operating Margin %	19.87
	Net Margin %	9.81
	EBITDA Margin %	39.17
	FCF Margin %	28.21
	OCF Margin %	28.21
	ROE %	4.17
	ROA %	1.98
	ROIC %	3.77
	3-Year ROIIC %	2.7
	ROC (Joel Greenblatt) %	19.99
	ROCE %	7.98
	Years of Profitability over Past 10-Year	9
	Moat Score	4
	Tariff Resilience Score	4

GF Value Rank

4/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	11.6
	Forward PE Ratio	13.18
	PE Ratio without NRI	11.6
	Shiller PE Ratio	7.85
	Price-to-Owner-Earnings	12.53
	PEG Ratio	1.93
	PS Ratio	1.14
	PB Ratio	0.46
	Price-to-Tangible-Book	0.89
	Price-to-Free-Cash-Flow	3.92
	Price-to-Operating-Cash-Flow	3.92
	EV-to-EBIT	6.92
	EV-to-Forward-EBIT	11.22
	EV-to-EBITDA	4.57
	EV-to-Forward-EBITDA	8.3
	EV-to-Revenue	1.79
	EV-to-Forward-Revenue	1.93
	EV-to-FCF	6.25
	Price-to-GF-Value	0.64
	Price-to-Projected-FCF	0.89
	Price-to-Median-PS-Value	0.54
	Price-to-Peter-Lynch-Fair-Value	3.4
	Price-to-Graham-Number	0.68
	Earnings Yield (Greenblatt) %	14.45
	FCF Yield %	23.26
	Forward Rate of Return (Yacktman) %	1.13

Financials

Annual Quarterly TTM

FRA:LUP's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Luye Pharma Group Ltd Executives

Details

GF Value™: €0.32

FRA:LUP

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with LUP. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	763.29
	EPS (TTM) (€)	0.019
	Beta	0.0682
	3-Year Sharpe Ratio	-0.21
	3-Year Sortino Ratio	-0.32
	Volatility %	39.57
	14-Day RSI	43.41
	14-Day ATR (€)	0.007436
	20-Day SMA (€)	0.20575
	12-1 Month Momentum %	-37.89
	52-Week Range (€)	0.193 - 0.482
	Shares Outstanding (Mil)	3,994.52

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Luye Pharma Group Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Luye Pharma Group Ltd Stock Events

Financials Calendars

	Event	Date	Price (€)
No Event Data

Luye Pharma Group Ltd Frequently Asked Questions

What is Luye Pharma Group Ltd(FRA:LUP)'s stock price today?

The current price of FRA:LUP is €0.20. The 52 week high of FRA:LUP is €0.48 and 52 week low is €0.19.

When is next earnings date of Luye Pharma Group Ltd(FRA:LUP)?

The next earnings date of Luye Pharma Group Ltd(FRA:LUP) is .

Does Luye Pharma Group Ltd(FRA:LUP) pay dividends? If so, how much?

Luye Pharma Group Ltd(FRA:LUP) does not pay dividend.

Press Release

	Subject	Date
	Luye Pharma Releases its Financial Results for the First Half of 2018: Double-Digit Growth in Core Product Sales, Exceeded Expectations in Sales, R&D and M&As	2018-08-29

10/Page

Articles on Luye Pharma Group Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.